COSMO Pharmaceuticals N.V. (CH:COPN)
:COPN
Want to see CH:COPN full AI Analyst Report?
Top Page
COSMO Pharmaceuticals N.V.
(COPN)
Select Model
Select Model
Rating:49Neutral
Price Target:
CHF72.00
▼(-26.38% Downside)
Action:Reiterated
Date:03/12/26
The score is driven primarily by unstable operating results and a sharp 2025 deterioration in profitability and cash generation, despite a very strong, low-leverage balance sheet. Weak technical momentum adds near-term risk, while valuation is constrained by negative earnings with only modest support from the ~2% dividend yield.
Positive Factors
Low-leverage balance sheet
Very low debt and substantial equity provide durable financial flexibility across a 2–6 month horizon. This conservatism supports funding of R&D, commercialization or partner deals without immediate refinancing pressure, cushioning the firm against cyclical revenue swings and cash volatility.
Negative Factors
Highly volatile revenue and earnings
Large swings in sales and margins undermine predictability for investment, hiring and R&D spending. Such volatility suggests outcomes hinge on episodic events or partner payments, complicating multi-quarter planning and raising execution risk for sustained growth and consistent profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low-leverage balance sheet
Very low debt and substantial equity provide durable financial flexibility across a 2–6 month horizon. This conservatism supports funding of R&D, commercialization or partner deals without immediate refinancing pressure, cushioning the firm against cyclical revenue swings and cash volatility.
Read all positive factors
COSMO Pharmaceuticals N.V. (COPN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.21B
Dividend Yield1.82%
Average Volume (3M)19.52K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth-61.60%
EPS Growth-102.68%
CountryCH
Employees321
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF143.33Price Target Upside46.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.1
Revenue Forecast (FY)CHF106.30M
COSMO Pharmaceuticals N.V. Business Overview & Revenue Model
Company Description
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formu...
How the Company Makes Money
Cosmo Pharmaceuticals makes money primarily through a mix of (1) sales of its own products where it commercializes directly and/or via distribution arrangements, and (2) partnering economics from out-licensing its products/technologies to other ph...
COSMO Pharmaceuticals N.V. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
86
Very Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 104.85M | 266.79M | 92.78M | 102.09M | 65.07M |
| Gross Profit | 48.78M | 246.92M | 53.44M | 83.33M | 49.93M |
| EBITDA | 2.36M | 165.71M | 19.70M | 46.74M | 17.81M |
| Net Income | -3.63M | 133.24M | -4.93M | 17.23M | 21.67M |
Balance Sheet | |||||
| Total Assets | 612.16M | 646.77M | 553.98M | 759.59M | 805.56M |
| Cash, Cash Equivalents and Short-Term Investments | 122.66M | 142.96M | 50.27M | 240.95M | 222.21M |
| Total Debt | 4.26M | 2.20M | 1.84M | 173.60M | 169.92M |
| Total Liabilities | 123.36M | 141.68M | 124.94M | 295.80M | 292.88M |
| Stockholders Equity | 481.92M | 498.33M | 422.16M | 456.93M | 505.28M |
Cash Flow | |||||
| Free Cash Flow | -15.85M | 156.76M | 18.31M | 25.92M | 4.11M |
| Operating Cash Flow | -11.62M | 162.41M | 22.71M | 33.23M | 12.61M |
| Investing Cash Flow | 49.85M | -128.88M | 42.30M | 1.69M | 24.86M |
| Financing Cash Flow | -24.61M | -40.22M | -211.27M | -46.13M | -27.25M |
COSMO Pharmaceuticals N.V. Technical Analysis
Negative
97.80
Price Trends
82.12
Negative
94.86
Negative
82.82
Negative
Market Momentum
-2.65
Positive
38.24
Neutral
18.39
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:COPN, the sentiment is Negative. The current price of 97.8 is above the 20-day moving average (MA) of 76.34, above the 50-day MA of 82.12, and above the 200-day MA of 82.82, indicating a bearish trend. The MACD of -2.65 indicates Positive momentum. The RSI at 38.24 is Neutral, neither overbought nor oversold. The STOCH value of 18.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:COPN.
COSMO Pharmaceuticals N.V. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF612.52M | 18.84 | ― | ― | 11.43% | -48.80% | |
56 Neutral | CHF743.83M | 490.31 | -7.82% | ― | 59.85% | ― | |
56 Neutral | CHF358.57M | 55.42 | ― | 4.54% | -7.42% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | CHF1.01B | 111.83 | ― | ― | 19.76% | 150.73% | |
49 Neutral | CHF1.21B | -356.67 | 11.46% | 1.82% | -61.60% | -102.68% |
* General Sector Average
CH:COPN
COSMO Pharmaceuticals N.V.
73.90
16.01
27.64%
CH:BSLN
Basilea Pharmaceutica
49.85
0.65
1.32%
CH:KURN
Kuros Biosciences
20.50
-4.30
-17.34%
CH:MEDX
medmix AG
8.72
-1.76
-16.82%
CH:MED
Medartis Holding AG
75.10
-2.10
-2.72%
COSMO Pharmaceuticals N.V. Corporate Events
Cosmo completes Phase II recruitment for novel ulcerative colitis therapy
May 18, 2026
Cosmo Pharmaceuticals has completed patient recruitment for a Phase II trial of its Rifamycin enema, an investigational treatment for distal ulcerative colitis and ulcerative proctitis, enrolling 77 patients across 24 European sites. The study wil...
Cosmo’s Clascoterone Delivers Strong 12‑Month Data in Male Hair Loss, Paving Way for 2027 Filings
Apr 15, 2026
Cosmo Pharmaceuticals has reported positive 12‑month Phase III data for its Clascoterone 5% topical solution in men with mild to moderate androgenetic alopecia, showing a safety profile comparable to placebo over a year and no significant sy...
Cosmo Shareholders Approve All AGM Resolutions and EUR 2.10 Dividend
Apr 10, 2026
Cosmo Pharmaceuticals reported that shareholders approved all agenda items at the 2026 Annual General Meeting, with 59.02% of outstanding ordinary shares represented. Investors backed a dividend of EUR 2.10 per share, with the ex-dividend date set...
Cosmo to Showcase Real-Time Medical AI Platforms at NVIDIA GTC 2026
Mar 16, 2026
Cosmo Pharmaceuticals will showcase its real-time medical AI capabilities at NVIDIA GTC 2026 in San Jose, highlighting its role in developing AI systems used during clinical procedures. The company will present a session titled “Engineering ...
Cosmo Sets April General Meeting with Name Change and Payout on Agenda
Mar 12, 2026
Cosmo Pharmaceuticals N.V. has convened its ordinary General Meeting for 10 April 2026 in Amsterdam, where shareholders will review the 2025 financial year and ESG achievements and decide on profit appropriation. The agenda also includes a propose...
Cosmo Pharmaceuticals Lifts Recurring Revenues, Boosts Dividend and Sets Growth Path to 2030
Mar 9, 2026
Cosmo Pharmaceuticals reported 2025 revenue of EUR 104.2 million, with recurring revenues rising 15% to EUR 88.1 million and now accounting for 85% of the total, while EBITDA reached EUR 9.5 million, above guidance despite a small operating loss d...
Cosmo teams with Dutch institutions to expand GI Genius AI into Barrett’s esophagus detection
Mar 5, 2026
Cosmo Pharmaceuticals has entered a strategic RD collaboration with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an AI-based detection system for early neoplasia in Barrett’s esophagus. The project ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.